Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Comorbidity Could Be Key To Alzheimer’s Clinical Trial Failures

XTALKS VITALS NEWS

Alzheimer's

Researchers estimate that up to 40 percent of Alzheimer’s patients also have vascular cognitive impairment and dementia.

Tweetables from this article:

Tweet: Up to 40 percent of #Alzheimers patients also have vascular cognitive impairment and #dementia http://ctt.ec/oz_da+ Up to 40 percent of Alzheimer’s patients also have vascular cognitive impairment and dementia.

Share this!

October 4, 2016 | by Sarah Hand, M.Sc.

Alzheimer’s disease is the number one cause of dementia, however another condition – known as vascular cognitive impairment and dementia – is a close second. Microinfarcts and strokes can impair blood flow to the brain, leading to the development of symptoms associated with this type of dementia.

While recognized as a distinct form of the disease, vascular cognitive impairment and dementia can occur in patients with Alzheimer’s disease. Researchers estimate that up to 40 percent of Alzheimer’s patients also have vascular cognitive impairment and dementia.

According to Dr. Donna Wilcock, of the University of Kentucky Sanders-Brown Center on Aging, the presence of multiple dementias in patients could be responsible for the failure of some immunotherapies in Alzheimer’s clinical trials. Wilcock and her colleagues published their findings in the Journal of Neuroscience.



“These findings are important in that they provide a possible explanation for why clinical trials of anti-Aβ immunotherapy for Alzheimer’s disease have been historically unsuccessful,” said Wilcock. “If up to 40 percent of people with Alzheimer's also have vascular cognitive impairment and dementia, treatment candidates that target only the Alzheimer’s disease physiology won't be effective in those patients. It's like treating only half the disease.”

As the accumulation of amyloid β (Aβ) containing plaques is thought to be a key factor in Alzheimer’s pathology, much research has been focused on identifying drugs capable of reducing Aβ buildup. Using immunotherapy, researchers have developed anti-Aβ antibodies capable of clearing plaques from the brain of animal models of the disease. Unfortunately, these immunotherapy approaches have so far failed in clinical trials of Alzheimer’s patients, leading developers to wonder why the approach has not be translatable.

“There has been one failure after another in clinical trials, which has been really disheartening for the scientific community and for patients,” said Wilcock. “My work might shed some early light on why they failed and eventually open the door for a combination treatment for vascular cognitive impairment and dementia, and Alzheimer’s disease.”

While mouse models of Alzheimer’s disease are already available, Wilcock and her colleagues needed to develop a combined animal model of both Alzheimer’s disease and vascular cognitive impairment and dementia, in order to perform their research. By comparing this combined model to an Alzheimer’s-only model, the researchers were able to test the efficacy of the anti-Aβ immunotherapy. They found that the antibody was capable of reducing Aβ plaques in both groups, however the combined animal model showed no improvement in cognitive function in response to treatment.

“The failure of anti-Aβ immunotherapy in the mixed Alzheimer’s disease-vascular cognitive impairment and dementia model suggests that both disease processes have to be treated to have a successful outcome,” said Wilcock. “The missing link has been that our animal models usually possess the hallmarks of only one disease, which has led to failure of successful translation to clinic.

“By developing a model that more accurately reflects the brain changes we see in the human brain with dementia, we can better develop our treatment approaches and increase our chances of successful translation. Our next step is to add a treatment for vascular cognitive impairment and dementia on top of the Aβ immunotherapy, to try to overcome the inability to produce a meaningful improvement in learning and memory.”


Keywords: Comorbidity, Alzheimer's Disease, Clinical Trials


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Researchers Identify Role of ApoE4 Gene as Possible Drug Target in Alzheimer’s Disease

September 21, 2017 - A team of neurology researchers at Washington University School of Medicine in St. Louis have found that in the presence of the ApoE4 protein, another protein known as tau forms tangles in the brain which contributes to neuronal damage characteristic of Alzheimer’s disease.

Featured In: Life Science News


New Guidelines Address CAR-T Immunotherapy Toxicities to Prevent Patient Deaths

September 20, 2017 - Clinicians at The University of Texas MD Anderson Cancer Center have published new guidelines in the journal, Nature Reviews Clinical Oncology, which could help in the management of these toxicities.

Featured In: Biotech News, Drug Safety News


Microneedle Skin Patch Could Treat Common Metabolic Disorders

September 19, 2017 - Researchers at Columbia University Medical Center (CUMC) and the University of North Carolina have developed a microneedle skin patch impregnated with a drug capable of converting white fat into calorie-burning brown fat.

Featured In: Medical Device News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Five Reasons Why Toronto is Emerging as a Major Life Sciences Hub

REGISTER FOR THESE WEBINARS

Development and Manufacture of Highly Potent API Drug Products Throughout the Clinical Phases


Innovation through Integration – Providing Next Generation Biomedical Devices and Interconnects


Clinical Payments Case Studies: Improving Efficiency, Cash Management, and Compliance


Why Phase 3 Trials Fail: Oncology Case Studies and Lessons Learned


Copyright © 2016-2017 Honeycomb Worldwide Inc.